Protagenic Therapeutics Inc
PTIX1.160USD
-0.075-6.07%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.24MMarket Cap
67.56P/E TTM
More Details of Protagenic Therapeutics Inc Company
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
Protagenic Therapeutics Inc Info
Ticker SymbolPTIX
Company nameProtagenic Therapeutics Inc
IPO dateDec 18, 1996
CEO- -
Number of employees1
Security typeOrdinary Share
Fiscal year-endDec 18
Address149 Fifth Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10010
Phone12129948200
Websitehttps://protagenic.com/
Ticker SymbolPTIX
IPO dateDec 18, 1996
CEO- -
Company Executives of Protagenic Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Alexander K. (Alex) Arrow, M.D.
Dr. Alexander K. (Alex) Arrow, M.D.
Chief Financial Officer
Chief Financial Officer
3.27K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Andrew Slee, Ph.D.
Dr. Andrew Slee, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
--
--
Mr. Colin Stott
Mr. Colin Stott
Director
Director
--
--
Ms. Jennifer M. Chao
Ms. Jennifer M. Chao
Director
Director
--
--
Mr. Timothy R. (Tim) Wright
Mr. Timothy R. (Tim) Wright
Independent Director
Independent Director
--
--
Mr. Barrett Evans
Mr. Barrett Evans
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Alexander K. (Alex) Arrow, M.D.
Dr. Alexander K. (Alex) Arrow, M.D.
Chief Financial Officer
Chief Financial Officer
3.27K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Andrew Slee, Ph.D.
Dr. Andrew Slee, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Dr. Robert Burton (Bob) Stein, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
--
--
Mr. Colin Stott
Mr. Colin Stott
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 17
Updated: Wed, Dec 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armen (Garo H.)
2.73%
DRW Securities, LLC
1.87%
Connective Capital Management, LLC
1.48%
FNY Investment Advisers LLC
0.90%
Armistice Capital LLC
0.89%
Other
92.13%
Shareholders
Shareholders
Proportion
Armen (Garo H.)
2.73%
DRW Securities, LLC
1.87%
Connective Capital Management, LLC
1.48%
FNY Investment Advisers LLC
0.90%
Armistice Capital LLC
0.89%
Other
92.13%
Shareholder Types
Shareholders
Proportion
Individual Investor
3.59%
Investment Advisor
2.65%
Hedge Fund
2.43%
Investment Advisor/Hedge Fund
0.90%
Research Firm
0.09%
Other
90.33%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
23
87.75K
4.55%
-39.26K
2025Q2
26
133.28K
15.40%
-106.32K
2025Q1
26
138.80K
16.34%
-98.38K
2024Q4
25
1.36M
18.85%
-1.89M
2024Q3
26
1.38M
22.53%
-1.83M
2024Q2
26
1.37M
22.48%
-1.80M
2024Q1
28
1.76M
40.25%
-850.74K
2023Q4
30
1.34M
30.68%
-1.27M
2023Q3
33
2.57M
59.42%
+1.03M
2023Q2
36
2.57M
59.44%
+1.02M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armen (Garo H.)
52.75K
2.75%
--
--
Mar 31, 2025
Armistice Capital LLC
17.14K
0.9%
--
--
Dec 31, 2024
Morgan Stanley Smith Barney LLC
15.00K
0.78%
+15.00K
--
Jun 30, 2025
Barrage (Khalil Z)
10.78K
0.56%
--
--
Mar 31, 2025
Arrow (Alexander K)
3.27K
0.17%
--
--
Mar 31, 2025
Lovejoy (David A)
2.66K
0.14%
--
--
Mar 31, 2025
Citi Investment Research (US)
390.00
0.02%
+390.00
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 29, 2025
Merger
14→1
Mar 22, 2023
Merger
4→1
Mar 22, 2023
Merger
4→1
Mar 22, 2023
Merger
4→1
Mar 22, 2023
Merger
4→1
Date
Type
Ratio
Apr 29, 2025
Merger
14→1
Mar 22, 2023
Merger
4→1
Mar 22, 2023
Merger
4→1
Mar 22, 2023
Merger
4→1
Mar 22, 2023
Merger
4→1
FAQs
Who are the top five shareholders of Protagenic Therapeutics Inc?
The top five shareholders of Protagenic Therapeutics Inc are:
Armen (Garo H.) holds 52.75K shares, accounting for 2.75% of the total shares.
Armistice Capital LLC holds 17.14K shares, accounting for 0.90% of the total shares.
Morgan Stanley Smith Barney LLC holds 15.00K shares, accounting for 0.78% of the total shares.
Barrage (Khalil Z) holds 10.78K shares, accounting for 0.56% of the total shares.
Arrow (Alexander K) holds 3.27K shares, accounting for 0.17% of the total shares.
Armen (Garo H.) holds 52.75K shares, accounting for 2.75% of the total shares.
Armistice Capital LLC holds 17.14K shares, accounting for 0.90% of the total shares.
Morgan Stanley Smith Barney LLC holds 15.00K shares, accounting for 0.78% of the total shares.
Barrage (Khalil Z) holds 10.78K shares, accounting for 0.56% of the total shares.
Arrow (Alexander K) holds 3.27K shares, accounting for 0.17% of the total shares.
What are the top three shareholder types of Protagenic Therapeutics Inc?
The top three shareholder types of Protagenic Therapeutics Inc are:
Armen (Garo H.)
DRW Securities, LLC
Connective Capital Management, LLC
Armen (Garo H.)
DRW Securities, LLC
Connective Capital Management, LLC
How many institutions hold shares of Protagenic Therapeutics Inc (PTIX)?
As of 2025Q3, 23 institutions hold shares of Protagenic Therapeutics Inc, with a combined market value of approximately 87.75K, accounting for 4.55% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.85%.
What is the biggest source of revenue for Protagenic Therapeutics Inc?
In --, the -- business generated the highest revenue for Protagenic Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
